Welcome to our dedicated page for Estrella Immunopharma news (Ticker: UPTDU), a resource for investors and traders seeking the latest updates and insights on Estrella Immunopharma stock.
Estrella Immunopharma, Inc., formerly known as TradeUP Acquisition Corp. (UPTD), successfully completed a business combination with Estrella Biopharma, Inc., focusing on T-cell therapies for blood cancers and solid tumors. Led by Dr. Cheng Liu, the company will operate under the name Estrella Immunopharma, Inc. The company's main product candidate, EB103, targets CD19 for B-cell leukemias and lymphomas, while EB104 targets CD19 and CD22 for B-cell malignancies. Estrella is also collaborating with Imugene Limited for oncolytic virus research.
TradeUP Acquisition Corp. (NASDAQ: UPTDU) announced that starting September 7, 2021, holders of its Units can separately trade the included common stock and warrants. The Units, initially sold in an IPO, will continue to trade under the symbol 'UPTDU.' The underlying common stock and warrants will trade under 'UPTD' and 'UPTDW,' respectively. This separation process requires holders to contact VStock Transfer, LLC. US Tiger Securities, Inc. was the lead manager of the IPO, which became effective on July 14, 2021.
TradeUp Acquisition Corp. (NASDAQ: UPTDU) has successfully closed its initial public offering (IPO), raising $44.3 million through the issuance of 4,430,000 units at $10.00 per unit. The offering, which included 430,000 units from an over-allotment option, commenced trading on the NASDAQ on July 15, 2021. Each unit comprises one common stock share and half a redeemable warrant, with warrants exercisable at $11.50 per share. The company is a blank check firm targeting potential mergers, primarily in the technology sector.
TradeUp Acquisition Corp. (NASDAQ: UPTDU) has priced its initial public offering (IPO) of 4,000,000 units at $10.00 each, set to trade on NASDAQ under the ticker symbol UPTDU from July 15, 2021. Each unit consists of one share of common stock and half a redeemable warrant, with each whole warrant exercisable at $11.50 per share. The company has granted underwriters a 45-day option to purchase an additional 600,000 units. The offering is expected to close on July 19, 2021.
FAQ
What is the main focus of Estrella Immunopharma, Inc.?
Who leads Estrella Immunopharma, Inc.?
What are the lead product candidates of Estrella Immunopharma, Inc.?
What collaboration does Estrella have with Imugene Limited?
What was the recent business combination involving Estrella?
What is the mission of Estrella Immunopharma, Inc.?
What were the key financing activities related to the business combination?
What is Dr. Cheng Liu's statement regarding the transaction?
What are the new trading symbols for the combined company post-merger?
Which legal firms served as advisors for the business combination?
What is the background of TradeUP Acquisition Corp.?
What is Estrella Immunopharma working on developing?
Who is leading Estrella Immunopharma?
What are the lead product candidates of Estrella Immunopharma?
What collaboration is Estrella part of with Imugene Limited?
What recent transaction did Estrella complete?
What is the main mission of Estrella Immunopharma?
What funding activities were associated with the business combination?
What are the trading symbols for the combined company post-merger?
Which firms provided advisory services for the business combination?
What was TradeUP Acquisition Corp. primarily formed for?
